BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33028706)

  • 1. Immunocytokines are a promising immunotherapeutic approach against glioblastoma.
    Weiss T; Puca E; Silginer M; Hemmerle T; Pazahr S; Bink A; Weller M; Neri D; Roth P
    Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
    Menssen HD; Harnack U; Erben U; Neri D; Hirsch B; Dürkop H
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):499-507. PubMed ID: 29327244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice.
    Puca E; De Luca R; Seehusen F; Rodriguez JMM; Neri D
    J Control Release; 2020 Jan; 317():282-290. PubMed ID: 31790729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8
    Puca E; Probst P; Stringhini M; Murer P; Pellegrini G; Cazzamalli S; Hutmacher C; Gouyou B; Wulhfard S; Matasci M; Villa A; Neri D
    Int J Cancer; 2020 May; 146(9):2518-2530. PubMed ID: 31374124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Kaspar M; Trachsel E; Neri D
    Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
    Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
    Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.
    Balza E; Carnemolla B; Mortara L; Castellani P; Soncini D; Accolla RS; Borsi L
    Int J Cancer; 2010 Jul; 127(1):101-10. PubMed ID: 19877124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy.
    Jung K; Yoo S; Kim JE; Kim W; Kim YS
    Front Immunol; 2022; 13():1034774. PubMed ID: 36405748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
    Winter J; Barbin K; Bacci C; Bunte T
    J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.
    Galbiati A; Dorten P; Gilardoni E; Gierse F; Bocci M; Zana A; Mock J; Claesener M; Cufe J; Büther F; Schäfers K; Hermann S; Schäfers M; Neri D; Cazzamalli S; Backhaus P
    J Nucl Med; 2023 Dec; 64(12):1934-1940. PubMed ID: 37734838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties
    Ongaro T; Gouyou B; Stringhini M; Corbellari R; Neri D; Villa A
    Oncotarget; 2020 Oct; 11(41):3698-3711. PubMed ID: 33110477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
    Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
    Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response of tissue-resident memory T cells against the AH1 rejection antigen.
    Stringhini M; Probst P; Neri D
    Eur J Immunol; 2020 Oct; 50(10):1591-1597. PubMed ID: 32470143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
    Zegers CM; Rekers NH; Quaden DH; Lieuwes NG; Yaromina A; Germeraad WT; Wieten L; Biessen EA; Boon L; Neri D; Troost EG; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Mar; 21(5):1151-60. PubMed ID: 25552483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 19. Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.
    Ongaro T; Guarino SR; Scietti L; Palamini M; Wulhfard S; Neri D; Villa A; Forneris F
    J Struct Biol; 2021 Mar; 213(1):107696. PubMed ID: 33493635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.
    Ziffels B; Pretto F; Neri D
    Immunotherapy; 2018 Mar; 10(3):177-188. PubMed ID: 29370721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.